Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
04:05pm, Wednesday, 30'th Oct 2024
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
04:02pm, Wednesday, 30'th Oct 2024
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointmen
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024
09:52pm, Thursday, 22'nd Aug 2024
Pulse Biosciences (NASDAQ: PLSE ) just reported results for the second quarter of 2024. Pulse Biosciences reported earnings per share of -20 cents.
Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript
06:50pm, Monday, 12'th Aug 2024
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffle
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
04:05pm, Thursday, 01'st Aug 2024
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
11:44am, Thursday, 01'st Aug 2024
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The investigation see
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
08:00am, Tuesday, 04'th Jun 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today annou
Pulse Biosciences Enhances Executive Leadership Team
04:05pm, Tuesday, 14'th May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”
Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript
01:29pm, Saturday, 11'th May 2024
Pulse Biosciences Inc (NASDAQ:PLSE ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Philip Taylor - Principal, Gilmartin Group LLC Kevin Danahy - President & CEO Michael
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
04:05pm, Tuesday, 07'th May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today annou
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
08:00am, Thursday, 02'nd May 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
04:05pm, Wednesday, 24'th Apr 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today annou
Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript
08:52pm, Thursday, 28'th Mar 2024
Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
04:12pm, Thursday, 28'th Mar 2024
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today annou
